B-MoGen Biotechnologies and CytoSen Therapeutics Sign an Agreement for the Development of Gene-Modified Therapies
Shots:
- The companies collaborated to develop gene-modified NK Cell therapies using CARs (Chimeric antigen receptor) and TCRs (T cell receptors) in the fields of oncology
- The focus of the agreement is to advance NK cell therapies with a reduction in its cost- combining B-MoGen’s genetic competence & its non-viral gene delivery platform with CytoSen’s nanoparticle technology
- B-MoGen’s TcBuster is a non-viral transposon-based gene therapy technology used for developing T-Cell immunotherapies for multiple therapy areas
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
